These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 8810278

  • 41. Crkl is the major tyrosine-phosphorylated protein in neutrophils from patients with chronic myelogenous leukemia.
    Oda T, Heaney C, Hagopian JR, Okuda K, Griffin JD, Druker BJ.
    J Biol Chem; 1994 Sep 16; 269(37):22925-8. PubMed ID: 8083188
    [Abstract] [Full Text] [Related]

  • 42. Tyrosine phosphorylation of p120cbl in BCR/abl transformed hematopoietic cells mediates enhanced association with phosphatidylinositol 3-kinase.
    Jain SK, Langdon WY, Varticovski L.
    Oncogene; 1997 May 08; 14(18):2217-28. PubMed ID: 9174058
    [Abstract] [Full Text] [Related]

  • 43. Insulin stimulates the tyrosine dephosphorylation of docking protein p130cas (Crk-associated substrate), promoting the switch of the adaptor protein crk from p130cas to newly phosphorylated insulin receptor substrate-1.
    Sorokin A, Reed E.
    Biochem J; 1998 Sep 15; 334 ( Pt 3)(Pt 3):595-600. PubMed ID: 9729467
    [Abstract] [Full Text] [Related]

  • 44. Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin.
    Oda A, Miyakawa Y, Druker BJ, Ishida A, Ozaki K, Ohashi H, Wakui M, Handa M, Watanabe K, Okamoto S, Ikeda Y.
    Blood; 1996 Dec 01; 88(11):4304-13. PubMed ID: 8943867
    [Abstract] [Full Text] [Related]

  • 45. v-Crk-induced cell transformation: changes in focal adhesion composition and signaling.
    Nievers MG, Birge RB, Greulich H, Verkleij AJ, Hanafusa H, van Bergen en Henegouwen PM.
    J Cell Sci; 1997 Feb 01; 110 ( Pt 3)():389-99. PubMed ID: 9057091
    [Abstract] [Full Text] [Related]

  • 46. Identification of p130Cas as a mediator of focal adhesion kinase-promoted cell migration.
    Cary LA, Han DC, Polte TR, Hanks SK, Guan JL.
    J Cell Biol; 1998 Jan 12; 140(1):211-21. PubMed ID: 9425168
    [Abstract] [Full Text] [Related]

  • 47. Association of the Cas-like molecule HEF1 with CrkL following integrin and antigen receptor signaling in human B-cells: potential relevance to neoplastic lymphohematopoietic cells.
    Astier A, Manié SN, Law SF, Canty T, Haghayghi N, Druker BJ, Salgia R, Golemis EA, Freedman AS.
    Leuk Lymphoma; 1997 Dec 12; 28(1-2):65-72. PubMed ID: 9498705
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.
    Panigrahi S, Stetefeld J, Jangamreddy JR, Mandal S, Mandal SK, Los M.
    PLoS One; 2012 Dec 12; 7(1):e28395. PubMed ID: 22253690
    [Abstract] [Full Text] [Related]

  • 51. Cellular interactions of CRKL, and SH2-SH3 adaptor protein.
    ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, Groffen J.
    Cancer Res; 1994 May 15; 54(10):2563-7. PubMed ID: 8168080
    [Abstract] [Full Text] [Related]

  • 52. Interactions of p62(dok) with p210(bcr-abl) and Bcr-Abl-associated proteins.
    Bhat A, Johnson KJ, Oda T, Corbin AS, Druker BJ.
    J Biol Chem; 1998 Nov 27; 273(48):32360-8. PubMed ID: 9822717
    [Abstract] [Full Text] [Related]

  • 53. Breast cancer anti-estrogen resistance 3 (BCAR3) protein augments binding of the c-Src SH3 domain to Crk-associated substrate (p130cas).
    Makkinje A, Vanden Borre P, Near RI, Patel PS, Lerner A.
    J Biol Chem; 2012 Aug 10; 287(33):27703-14. PubMed ID: 22711540
    [Abstract] [Full Text] [Related]

  • 54. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells.
    Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, Salgia R, Lipkowitz S, Griffin JD.
    Oncogene; 2002 Feb 21; 21(9):1423-33. PubMed ID: 11857085
    [Abstract] [Full Text] [Related]

  • 55. The two major sites of cbl tyrosine phosphorylation in abl-transformed cells select the crkL SH2 domain.
    Andoniou CE, Thien CB, Langdon WY.
    Oncogene; 1996 May 02; 12(9):1981-9. PubMed ID: 8649859
    [Abstract] [Full Text] [Related]

  • 56. Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells.
    Grumbach IM, Mayer IA, Uddin S, Lekmine F, Majchrzak B, Yamauchi H, Fujita S, Druker B, Fish EN, Platanias LC.
    Br J Haematol; 2001 Feb 02; 112(2):327-36. PubMed ID: 11167825
    [Abstract] [Full Text] [Related]

  • 57. Interaction of Bcr/Abl with C3G, an exchange factor for the small GTPase Rap1, through the adapter protein Crkl.
    Cho YJ, Hemmeryckx B, Groffen J, Heisterkamp N.
    Biochem Biophys Res Commun; 2005 Aug 12; 333(4):1276-83. PubMed ID: 15982636
    [Abstract] [Full Text] [Related]

  • 58. A switch from p130Cas/Crk to Gab1/Crk signaling correlates with anchorage independent growth and JNK activation in cells transformed by the Met receptor oncoprotein.
    Lamorte L, Kamikura DM, Park M.
    Oncogene; 2000 Dec 07; 19(52):5973-81. PubMed ID: 11146548
    [Abstract] [Full Text] [Related]

  • 59. The adapter protein Crkl links Cbl to C3G after integrin ligation and enhances cell migration.
    Uemura N, Griffin JD.
    J Biol Chem; 1999 Dec 31; 274(53):37525-32. PubMed ID: 10608804
    [Abstract] [Full Text] [Related]

  • 60. Networks of interaction of p120cbl and p130cas with Crk and Grb2 adaptor proteins.
    Khwaja A, Hallberg B, Warne PH, Downward J.
    Oncogene; 1996 Jun 20; 12(12):2491-8. PubMed ID: 8700507
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.